Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside

Sarepta Therapeutics TodaySRPTSarepta Therapeutics$18.80 +0.86 (+4.78%) 52-Week Range$10.41▼$144.22Price Target$44.17Add to WatchlistFor Sarepta Therapeutics NASDAQ: SRPT, 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), known as ELEVIDYS. Since gaining approval in June 2023, Sarepta has generated over $1 billion in revenue from ELEVIDYS. However, that success has b ...